Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of both St. Joseph's OSI Clinic Psychiatrists and patients towards PGx. Both OSI Clinic Psychiatrists participants and patient participants will be administered a brief demographic survey in addition to a survey examining their views on, and current knowledge of PGx. Patient participants will have an opportunity to opt-in to or opt-out of receiving PGx. For patient participants who opt-in to PGx (PGx-guided treatment group), a report summarizing the PGx results will be sent to each patient participants' respective OSI Clinic Psychiatrist, alongside a questionnaire that captures the OSI Clinic Psychiatrist participant's treatment planning and changes to treatment planning. Where applicable, past treatment data from patient participants acquired at the St. Joseph's OSI Clinic will be used to identify the number of prior medication changes. Patient participants who opt-out of PGx but continue to receive pharmacologic care at the St. Joseph's OSI Clinic will act as a standard care comparator treatment group. Patient participant's outcomes including PTSD, depression and anxiety severity, and medication-related side effects, will be assessed until the patient participant is discharged from the OSI Clinic or after 24 weeks, whichever comes first. All patient participants, regardless of their study treatment group, will have their symptomatology collected via standard care data collection protocol (Client Reported Outcomes Monitoring Information System (CROMIS) and electronic medical records (EMR)); a self-report assessing the presence of side effects will be completed via Lawson REDCap. OSI Clinic Psychiatrist participants and patient participants will be asked to complete a virtual exit interview at the end of their participation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mental Health Provider | No Intervention | Mental health provider's thoughts on pharmacogenetic testing for treatment planning and changes to treatment planning. | |
| Patient with Pharmacogenetic Testing | Experimental | For patient participants who opt-in to pharmacogenetic testing, a report summarizing the pharmacogenetic testing results will be sent to each patient participants' respective mental health provider. |
|
| Patient without Pharmacogenetic Testing | No Intervention | For patient participants who opt-out to pharmacogenetic testing will be followed to see if treatment course is maintained. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmacogenetics Testing | Genetic | Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| PHQ-9 - Patient Health Questionnaire 9 | Objectifies degree of depression severity | 5 minutes |
| GAD-7 - General Anxiety Disorder-7 | Measures severity of anxiety | 5 minutes |
| PCL-5 - Posttraumatic Stress Disorder Checklist - 5 | A 20-item self-report tool that corresponds to the 20 symptoms listed in the DSM-V | 5 minutes |
| OQ-45 - Outcome Questionnaire 45 | A 45-item multiple-choice self-report inventory used to measure psychotherapy progress in adult patients | 10 minutes |
| Pharmacological Side Effect Measure | To determine if the participant is experiencing any new or worsening or continuing side effects related to prescription medications | 10 minutes |
| Electronic Medical Record Extraction Measure | To determine trial and error attempts with pharmacological prescriptions in an attempt to minimize and/or control symptoms | 10 minutes |
Not provided
Not provided
Inclusion Criteria:
Provider participant:
Are at least 18 years of age;
Speak and write English;
Currently working as an OSI Clinic Psychiatrist at the London St. Joseph's OSI Clinic.
Patient participant:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Natalie Ein, PhD | Contact | 416-573-9047 | natalie.ein@sjhc.london.on.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MacDonald Franklin OSI Research and Innovation Centre | Recruiting | London | Ontario | N6C 0A7 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided